Decentralized Trial Technology Solutions
-
Introducing One Home for Sites™
2/8/2024
One Home for Sites is a vendor-agnostic, sponsor-agnostic, aggregation platform that provides single sign-on and more. Become part of the only industry-wide solution to site tech overload.
-
Patient-First Solutions For Oncology
11/16/2022
Stay connected with your patients and their data by simplifying collection for sites and sponsors while keeping participants safe, comfortable, and engaged from any location.
-
ECG Technology Chosen To Optimize Clinical Trial Success
10/22/2024
Improve the patient outcomes and data integrity of your clinical trials with ECG solutions.
-
TrialKit Engage For Televisits
12/29/2025
Conduct secure video based visits, manage study schedules, and keep participants connected through a single unified platform.
-
Transform Clinical Trials With Cognizant SIP: Efficient, Collaborative, Virtual
10/10/2022
Cognizant Shared Investigator Platform (SIP) provides a single point of access for multiple clinical trial resources across sponsors and investigation sites.
-
Direct-to-Patient Supply Management
5/15/2024
Signant SmartSignals RTSM simplifies direct-to-patient medication, offering at-home delivery with site and patient visibility. Flexible to accommodate various regulations.
-
It's Time To Move Into One Home for Sites
10/7/2025
Explore a vendor- and sponsor-neutral platform that streamlines trial management by consolidating systems and tasks.
-
BioPharma Services: Mobile Phlebotomy
2/21/2025
Explore how mobile phlebotomy is transforming clinical trial participation by making specimen collection more accessible, convenient, and patient-centric.
-
Decentralized Trials Support: Direct-To-Patient Supply Management
8/25/2025
Direct-to-patient shipments are reshaping decentralized trials by placing patient convenience at the center of study design.
-
Signant SmartSignals® Advisory
5/15/2024
Safeguard your protocol and endpoint data integrity with our expert support team, increasing your confidence, reducing workloads, and minimizing risks in data quality across all trial phases.